[
  {
    "ts": null,
    "headline": "Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It",
    "summary": "Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.",
    "url": "https://finnhub.io/api/news?id=c0158f8973ea567a6d76940bebc1d0d34c15faaa7cdb754a325ba4bb8b922dc0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744668955,
      "headline": "Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It",
      "id": 133917859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.",
      "url": "https://finnhub.io/api/news?id=c0158f8973ea567a6d76940bebc1d0d34c15faaa7cdb754a325ba4bb8b922dc0"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial",
    "summary": "PRINCETON, N.J., April 14, 2025--Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial",
    "url": "https://finnhub.io/api/news?id=85f0d85205e41e2c4ac1c48ce4ac8bab2003cd2aa81e62c4309ea1a2ff0d7d51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744661700,
      "headline": "Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial",
      "id": 133917860,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., April 14, 2025--Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial",
      "url": "https://finnhub.io/api/news?id=85f0d85205e41e2c4ac1c48ce4ac8bab2003cd2aa81e62c4309ea1a2ff0d7d51"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors despite daily gains",
    "summary": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=1f5ed837ec4ff60f1364fb7866d186cc2ae920e516b2522e853205dd7255571b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744648620,
      "headline": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors despite daily gains",
      "id": 133915346,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=1f5ed837ec4ff60f1364fb7866d186cc2ae920e516b2522e853205dd7255571b"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=f23fb937a7359484495dcaf631e006f7cfd07f4facc440f5daec602ee44369e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744635613,
      "headline": "Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know",
      "id": 133908438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=f23fb937a7359484495dcaf631e006f7cfd07f4facc440f5daec602ee44369e3"
    }
  },
  {
    "ts": null,
    "headline": "BMS’ Opdivo combo approved in US for hepatocellular carcinoma",
    "summary": "The approval is anchored in the outcomes from the open-label randomised Phase III CheckMate-9DW trial.",
    "url": "https://finnhub.io/api/news?id=b59b4feb810d8fee4afd9c99a69bc4a9e071d4e1751273eff542f3f59f49dfe8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744619537,
      "headline": "BMS’ Opdivo combo approved in US for hepatocellular carcinoma",
      "id": 133908439,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The approval is anchored in the outcomes from the open-label randomised Phase III CheckMate-9DW trial.",
      "url": "https://finnhub.io/api/news?id=b59b4feb810d8fee4afd9c99a69bc4a9e071d4e1751273eff542f3f59f49dfe8"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: new approval for Opdivo+Yervoy",
    "summary": "Bristol Myers Squibb announces that the FDA has approved the combination of Opdivo and Yervoy as first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma ....",
    "url": "https://finnhub.io/api/news?id=d47771d6f923a660eacd288471942ac1972a9f7d7d86ced5eb411be54b194b8c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744605135,
      "headline": "Bristol Myers: new approval for Opdivo+Yervoy",
      "id": 133904953,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb announces that the FDA has approved the combination of Opdivo and Yervoy as first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma ....",
      "url": "https://finnhub.io/api/news?id=d47771d6f923a660eacd288471942ac1972a9f7d7d86ced5eb411be54b194b8c"
    }
  }
]